Adaptive antimicrobial resistance, a description of microbial variants, and their relevance to periprosthetic joint infection.

Anti-Bacterial Agents / pharmacology Anti-Infective Agents / therapeutic use Arthritis, Infectious / drug therapy Drug Resistance, Bacterial Humans Prosthesis-Related Infections / drug therapy
Adaptive resistance Microbial variants PJI Periprosthetic joint infection Periprosthetic joint infection (PJI) Persister cells Phoenix colonies Small colony variants Transient antimicrobial resistance Transient hypermutability Variant selection antibiotic antimicrobial agents biofilms calcium sulphate clinicians organism(s) surgical debridement toxin

Journal

The bone & joint journal
ISSN: 2049-4408
Titre abrégé: Bone Joint J
Pays: England
ID NLM: 101599229

Informations de publication

Date de publication:
May 2022
Historique:
entrez: 2 5 2022
pubmed: 3 5 2022
medline: 4 5 2022
Statut: ppublish

Résumé

Periprosthetic joint infection (PJI) is a difficult complication requiring a comprehensive eradication protocol. Cure rates have essentially stalled in the last two decades, using methods of antimicrobial cement joint spacers and parenteral antimicrobial agents. Functional spacers with higher-dose antimicrobial-loaded cement and antimicrobial-loaded calcium sulphate beads have emphasized local antimicrobial delivery on the premise that high-dose local antimicrobial delivery will enhance eradication. However, with increasing antimicrobial pressures, microbiota have responded with adaptive mechanisms beyond traditional antimicrobial resistance genes. In this review we describe adaptive resistance mechanisms that are relevant to the treatment of PJI. Some mechanisms are well known, but others are new. The objective of this review is to inform clinicians of the known adaptive resistance mechanisms of microbes relevant to PJI. We also discuss the implications of these adaptive mechanisms in the future treatment of PJI. Cite this article:

Identifiants

DOI: 10.1302/0301-620X.104B5.BJJ-2021-1759.R1 PMID: 35491584 PMC: PMC9948434
pubmed: 35491584
doi: 10.1302/0301-620X.104B5.BJJ-2021-1759.R1
pmc: PMC9948434
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

575-580

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM124436
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR059033
Pays : United States

Références

Bone Joint J. 2020 Jun;102-B(6_Supple_A):158-162
pubmed: 32475268
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32540981
Sci Rep. 2016 Aug 25;6:32031
pubmed: 27558777
Appl Environ Microbiol. 2013 Dec;79(23):7116-21
pubmed: 24038684
Antimicrob Agents Chemother. 2006 Mar;50(3):841-51
pubmed: 16495241
Bone Joint Res. 2018 Nov 03;7(10):570-579
pubmed: 30464837
Clin Microbiol Rev. 2012 Oct;25(4):661-81
pubmed: 23034325
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1154-9
pubmed: 20080608
Front Immunol. 2019 Jul 23;10:1724
pubmed: 31396229
Trop Med Infect Dis. 2020 Dec 11;5(4):
pubmed: 33322463
J Bone Jt Infect. 2021 Nov 10;6(9):405-412
pubmed: 34804775
J Arthroplasty. 2020 Jun;35(6):1696-1702.e1
pubmed: 32192834
Bone Joint J. 2021 Jun;103-B(6 Supple A):13-17
pubmed: 34053300
Front Immunol. 2017 Dec 07;8:1678
pubmed: 29270167
Gastroenterology. 2011 Oct;141(4):1314-22, 1322.e1-5
pubmed: 21745447
Clin Orthop Relat Res. 2002 Oct;(403):8-15
pubmed: 12360001
Bone Joint J. 2021 Nov;103-B(11):1702-1708
pubmed: 34719272
mBio. 2014 Sep 30;5(5):e01910-14
pubmed: 25271290
FEMS Microbiol Rev. 2011 Sep;35(5):768-89
pubmed: 21645016
Nat Rev Microbiol. 2006 Apr;4(4):295-305
pubmed: 16541137
Bone Res. 2020 Dec 10;8(1):43
pubmed: 33303744
J Bone Joint Surg Am. 2007 Apr;89(4):780-5
pubmed: 17403800
Iran J Pathol. 2020 Spring;15(2):127-133
pubmed: 32215028
EFORT Open Rev. 2019 Jul 29;4(7):482-494
pubmed: 31423332
Toxins (Basel). 2016 Jul 09;8(7):
pubmed: 27409636
Clin Infect Dis. 1997 Nov;25(5):1250-1
pubmed: 9402396
Bone Joint Res. 2020 Dec;9(12):870-872
pubmed: 33307769
Antibiotics (Basel). 2020 Aug 27;9(9):
pubmed: 32867208
Microb Drug Resist. 2020 Jun;26(6):537-544
pubmed: 31825276
Acta Orthop. 2021 Aug;92(4):431-435
pubmed: 33977828
Am J Orthop (Belle Mead NJ). 1999 Mar;28(3):161-5
pubmed: 10195839
Int J Med Microbiol. 2020 Feb;310(2):151400
pubmed: 32001143
Biofilm. 2021 Aug 21;3:100056
pubmed: 34471871
Iran J Microbiol. 2012 Jun;4(2):98-9
pubmed: 22973477
Science. 2003 May 30;300(5624):1404-9
pubmed: 12775833
Clin Infect Dis. 1995 Jan;20(1):95-102
pubmed: 7727677
Elife. 2017 May 02;6:
pubmed: 28460660

Auteurs

Christopher Hamad (C)

Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Madhav Chowdhry (M)

Nuffield Department of Primary Care Health Sciences, Kellogg College, University of Oxford, Oxford, UK.

Devin Sindeldecker (D)

Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, USA.
Biomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio, USA.

Nicholas M Bernthal (NM)

Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Paul Stoodley (P)

Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, USA.
Department of Orthopaedics, The Ohio State University, Columbus, Ohio, USA.
National Centre for Advanced Tribology at Southampton, Department of Mechanical Engineering, University of Southampton, Southampton, UK.

Edward J McPherson (EJ)

Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Adaptive antimicrobial resistance, a...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Adaptive antimicrobial resistance, a...
questionsmedicales.fr › Maladies ostéomusculaires › Maladies articulaires › Arthrite › Arthrite infectieuse › Adaptive antimicrobial resistance, a...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance bactérienne aux médicaments › Adaptive antimicrobial resistance, a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Adaptive antimicrobial resistance, a...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Complications postopératoires › Infections dues aux prothèses › Adaptive antimicrobial resistance, a...